Bristol Myers Squibb Company $BMY Shares Sold by Trilogy Capital Inc.

Trilogy Capital Inc. trimmed its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 13.8% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 4,638 shares of the biopharmaceutical company’s stock after selling 740 shares during the period. Trilogy Capital Inc.’s holdings in Bristol Myers Squibb were worth $215,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. QTR Family Wealth LLC lifted its position in shares of Bristol Myers Squibb by 28.8% during the 2nd quarter. QTR Family Wealth LLC now owns 8,541 shares of the biopharmaceutical company’s stock worth $395,000 after purchasing an additional 1,911 shares during the last quarter. Trust Co. of Vermont lifted its holdings in Bristol Myers Squibb by 2.3% during the 2nd quarter. Trust Co. of Vermont now owns 44,871 shares of the biopharmaceutical company’s stock worth $2,077,000 after buying an additional 1,023 shares during the last quarter. OLD Point Trust & Financial Services N A lifted its holdings in Bristol Myers Squibb by 9.7% during the 2nd quarter. OLD Point Trust & Financial Services N A now owns 16,301 shares of the biopharmaceutical company’s stock worth $755,000 after buying an additional 1,440 shares during the last quarter. MBA Advisors LLC boosted its position in shares of Bristol Myers Squibb by 13.0% during the 2nd quarter. MBA Advisors LLC now owns 6,766 shares of the biopharmaceutical company’s stock worth $313,000 after acquiring an additional 776 shares in the last quarter. Finally, Emerald Advisors LLC increased its holdings in shares of Bristol Myers Squibb by 18.4% in the 2nd quarter. Emerald Advisors LLC now owns 19,293 shares of the biopharmaceutical company’s stock valued at $893,000 after acquiring an additional 2,995 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Insider Activity at Bristol Myers Squibb

In related news, EVP David V. Elkins sold 56,000 shares of the stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the completion of the sale, the executive vice president directly owned 167,379 shares of the company’s stock, valued at $7,922,048.07. This trade represents a 25.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.09% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Daiwa America downgraded Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 5th. Daiwa Capital Markets cut shares of Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 target price for the company. in a report on Tuesday, August 5th. Wall Street Zen lowered shares of Bristol Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Friday, June 6th. Citigroup reduced their price target on shares of Bristol Myers Squibb from $51.00 to $47.00 and set a “neutral” rating for the company in a research report on Friday, August 1st. Finally, Morgan Stanley reaffirmed a “hold” rating on shares of Bristol Myers Squibb in a report on Thursday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fifteen have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $56.38.

Bristol Myers Squibb Trading Down 3.5%

Shares of Bristol Myers Squibb stock opened at $45.75 on Friday. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21. The company has a market capitalization of $93.12 billion, a P/E ratio of 18.45, a PEG ratio of 2.43 and a beta of 0.33. Bristol Myers Squibb Company has a 1 year low of $42.96 and a 1 year high of $63.33. The company’s fifty day moving average is $46.42 and its two-hundred day moving average is $48.76.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share for the quarter, topping the consensus estimate of $1.07 by $0.39. The business had revenue of $12.27 billion during the quarter, compared to the consensus estimate of $11.32 billion. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The business’s quarterly revenue was up .6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.07 earnings per share. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. Analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, November 3rd. Stockholders of record on Friday, October 3rd will be issued a $0.62 dividend. The ex-dividend date of this dividend is Friday, October 3rd. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.4%. Bristol Myers Squibb’s payout ratio is presently 100.00%.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.